Related Experiment Videos
Potential for specific cancer therapy with immune T lymphocytes
Journal of Biological Response Modifiers
|January 1, 1984
Summary
Advanced tumors can be treated using T cells, with chemotherapy enhancing effectiveness. Non-cytotoxic T cells, supported by Interleukin-2 (IL-2), are sufficient for tumor eradication, offering a promising cancer therapy approach.
Area of Science:
- Immunology
- Cancer Therapy
- Cellular Immunology
Background:
- Advanced tumors can be eradicated by T lymphocytes in animal models.
- Successful therapy often requires low tumor burden and host immunosuppression.
- Chemotherapy can fulfill these requirements, enabling combined chemo-immunotherapy models.
Purpose of the Study:
- To investigate the efficacy of T cell-based therapy for advanced malignancies.
- To determine the role of different T cell subsets in tumor eradication.
- To evaluate the impact of Interleukin-2 (IL-2) on T cell therapy.
Main Methods:
- Utilized animal models with advanced syngeneic malignancies.
- Combined chemotherapy with T cell infusions.
- Cultured T lymphocytes long-term in vitro with IL-2.
- Administered IL-2 in vivo to augment T cell responses.
Main Results:
- Tumor eradication was achieved without cytotoxic T lymphocytes, using only helper/inducer T cells.
- Non-cytotoxic T cells mediated tumor elimination via delayed-type hypersensitivity.
- Long-term cultured T lymphocytes, dependent on IL-2, showed therapeutic effects.
- In vivo IL-2 administration enhanced the growth and efficacy of these cultured T cells.
Conclusions:
- Non-cytotoxic T cells are sufficient for tumor eradication in chemo-immunotherapy models.
- Interleukin-2 (IL-2) is crucial for expanding and sustaining therapeutic T cells both in vitro and in vivo.
- IL-2 administration can significantly improve the efficacy of T cell-based cancer therapy for established tumors.